HK1045996B - 用於治療脈管併發症的化合物，其製備方法及治療應用 - Google Patents

用於治療脈管併發症的化合物，其製備方法及治療應用

Info

Publication number
HK1045996B
HK1045996B HK02107559.6A HK02107559A HK1045996B HK 1045996 B HK1045996 B HK 1045996B HK 02107559 A HK02107559 A HK 02107559A HK 1045996 B HK1045996 B HK 1045996B
Authority
HK
Hong Kong
Prior art keywords
treatment
age
compounds
discloses
related diseases
Prior art date
Application number
HK02107559.6A
Other languages
English (en)
Other versions
HK1045996A1 (en
Inventor
Sankaranarayanan Alangudi
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of HK1045996A1 publication Critical patent/HK1045996A1/xx
Publication of HK1045996B publication Critical patent/HK1045996B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
HK02107559.6A 2001-03-21 2002-10-17 用於治療脈管併發症的化合物，其製備方法及治療應用 HK1045996B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01201057A EP1243581B1 (en) 2001-03-21 2001-03-21 Pyridinium compounds useful for the treatment of AGE-related diseases
JP2001081819A JP4471141B2 (ja) 2001-03-21 2001-03-22 老化関連及び糖尿病脈管合併症の管理のための新規化合物、その製造方法及び治療的使用
CA002341949A CA2341949C (en) 2001-03-21 2001-03-23 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses
CNB01112413XA CN1148351C (zh) 2001-03-21 2001-03-30 用于治疗脉管并发症的化合物,其制备方法及治疗应用

Publications (2)

Publication Number Publication Date
HK1045996A1 HK1045996A1 (en) 2002-12-20
HK1045996B true HK1045996B (zh) 2006-02-03

Family

ID=27427687

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107559.6A HK1045996B (zh) 2001-03-21 2002-10-17 用於治療脈管併發症的化合物，其製備方法及治療應用

Country Status (10)

Country Link
EP (1) EP1243581B1 (zh)
JP (1) JP4471141B2 (zh)
CN (1) CN1148351C (zh)
AT (1) ATE299496T1 (zh)
CA (1) CA2341949C (zh)
DE (1) DE60111919T2 (zh)
DK (1) DK1243581T3 (zh)
ES (1) ES2243389T3 (zh)
HK (1) HK1045996B (zh)
PT (1) PT1243581E (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2254563A2 (en) * 2008-01-25 2010-12-01 Torrent Pharmaceuticals Ltd. Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc
EP2349264A1 (en) * 2008-11-17 2011-08-03 Technische Universität München Pyrimidinium derivatives for use in the treatment or prevention of diabetes
AU2010245596A1 (en) * 2009-05-07 2011-12-22 Torrent Pharmaceuticals Limited Piperidine derivatives useful for treatment of diebetes
MY182914A (en) 2015-04-08 2021-02-05 Torrent Pharmaceuticals Ltd Pyridinium compounds
CA2997463A1 (en) 2015-04-08 2016-10-13 Torrent Pharmaceuticals Limited Pharmaceutical formulations
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze
JPH0232006A (ja) * 1988-07-21 1990-02-01 Shiseido Co Ltd 皮膚外用剤
JP2817219B2 (ja) * 1988-09-08 1998-10-30 武田薬品工業株式会社 カルバジン酸誘導体、その製造法及び製剤
JPH08175995A (ja) * 1994-12-21 1996-07-09 Green Cross Corp:The 糖化蛋白変成物質生成阻害剤
DE69629176T2 (de) * 1995-01-18 2004-06-03 Alteon Inc. Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
ES2183171T3 (es) * 1996-05-08 2003-03-16 Alteon Inc Sales de imidazolio sustituido y su uso para la inhibicion del envejecimiento de proteinas.
JP2001519813A (ja) * 1997-04-04 2001-10-23 スミスクライン・ビーチャム・コーポレイション カルシウム溶解性化合物
JPH11106352A (ja) * 1997-08-08 1999-04-20 Chugai Pharmaceut Co Ltd 糖尿病合併症治療剤
JPH11292881A (ja) * 1998-04-02 1999-10-26 Shionogi & Co Ltd １Ｈ−ピロロ［３，２−ｃ］ピリジニウム誘導体
WO2001025209A1 (en) * 1999-10-06 2001-04-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications
EP1222171B1 (en) * 1999-10-06 2004-02-25 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
JP2003137783A (ja) * 2001-10-19 2003-05-14 Torrent Pharmaceuticals Ltd 美容及び治療用途におけるピリジニウム誘導体の使用のための組成物及び方法

Also Published As

Publication number Publication date
ATE299496T1 (de) 2005-07-15
DK1243581T3 (da) 2005-10-31
PT1243581E (pt) 2005-11-30
CA2341949A1 (en) 2002-09-23
EP1243581B1 (en) 2005-07-13
CA2341949C (en) 2005-10-11
JP2002275158A (ja) 2002-09-25
CN1377880A (zh) 2002-11-06
ES2243389T3 (es) 2005-12-01
EP1243581A1 (en) 2002-09-25
DE60111919D1 (de) 2005-08-18
CN1148351C (zh) 2004-05-05
DE60111919T2 (de) 2006-04-20
JP4471141B2 (ja) 2010-06-02
HK1045996A1 (en) 2002-12-20

Similar Documents

Publication Publication Date Title
ATE508738T1 (de) System zur beabstandeten abgabe von arzneimitteln
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
Esper et al. The effect of two phototherapy protocols on pain control in orthodontic procedure—a preliminary clinical study
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
IL208184A0 (en) Glp-1, and methods for treating diabetes
CA2503810A1 (en) Therapeutic agent for fibromyalgia
RS50735B (sr) Medikamenti koji sadrže betamimetik lekove i novi lek antiholinesteraze
ATE92762T1 (de) Medikamente.
KR100516676B1 (ko) 안면 수술에서의 레보부피바카인의 용도
WO2001089494A8 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
HK1045996A1 (en) Pyridinium compounds useful for the treatment of age-related diseases
BR9915962A (pt) Composto da série do piridìnio, processos para a preparação de composto da série do piridìnio e de uma formulação parenteral, uso de um composto, composição farmacêutica para tratar complicações diabéticas e doenças associadas ao envelhecimento, e, método para tratar um paciente diabético e para prevenir ou tratar doenças causadas por complicações associadas à diabetes e ao envelhecimento
Siebert et al. Case Report Pseudomonas Puncture Wound Osteomyelitis in Adults
AU3401093A (en) Therapeutic agent for threatened abortion
AU6069794A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs
HUP0001097A2 (hu) COMT-inhibitorok alkalmazása cukorbetegséggel kapcsolatos érrendszeri rendellenességek megelőzésére alkalmas gyógyszerkészítmények előállítására
RU2267335C1 (ru) Способ комбинированной анальгезии у пожилых пациентов после операций на тазобедренном суставе и бедре
Mahinrad Complications and techniques of local anesthesia in oral and maxillofacial surgery
Sbarbaro 38. What are the advantages of direct observation of treatment?
RU96115219A (ru) Способ лечения больных сахарным диабетом
WO2004082578A3 (en) Use of soluble cd14 for treatment of diseases
RU2001125198A (ru) Способ щадящей терапии опухолевых заболеваний
UA45827A (uk) Спосіб комплексного лікування хворих з гнійно-некротичними ускладненнями синдрому діабетичної стопи

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210320